---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-012498"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:47:03.570585+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "medium"
source: SEC EDGAR
---

# Pulse Biosciences posts investor deck with nsPFA cath lab study details and 2026 goals

## Summary
- New details disclosed on pivotal clinical study of nsPFA Cardiac Catheter for atrial fibrillation.
- Next-generation nPulse cardiac catheter under development described in the deck.
- 2026 corporate goals summarized across electrophysiology, cardiac surgery, and soft tissue ablation.

## SEC filing metadata
- accession: 0001437749-26-012498
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774926012498/0001437749-26-012498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774926012498/plse20260415_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-012498
- JSON: https://secwatch.observer/filing/0001437749-26-012498.json
- Plain text: https://secwatch.observer/filing/0001437749-26-012498.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.